Travere therapeutics reports second quarter 2024 financial results

Received 521 new patient start forms (psfs) for filspari ® (sparsentan) in the quarter representing the sixth consecutive quarter of psf growth; total of 2,484 psfs received since launch

TVTX Ratings Summary

TVTX Quant Ranking